Abstract Search

ea0055oc3 | National Clinical Cases | SFEEU2018

Hyperprolactinaemia resistant to dopamine agonist due to an ectopic source of prolactin arising from a Uterine Tumour Resembling Ovarian Sex Cord Tumours (UTROCST)

Bakhit Mohamed , Arshad Sobia , Bidmead John , Haq Masud , Lewis Dylan , Diaz-Cano Salvador , Aylwin Simon J. B.

Introduction: Moderate hyperprolactinaemia occurring in a patient with a normal pituitary MRI, assuming macroprolactin and stress are excluded, is generally considered to be due to a lesion below the level of detection of the MRI scanner. Most patients with mild-moderate hyperprolactinaemia and a normal MRI respond to dopamine agonist therapy. We describe a patient who had prolactin elevation typical of a prolactin-secreting macroadenoma, but with a normal MRI, and in whom the...

0 shares

ea0038p315 | Pituitary | SFEBES2015

Expression of MGMT in a large series of pituitary adenomas: lactotroph and corticotroph adenomas are more likely to be MGMT-negative than somatotroph and gonadotroph adenomas

Dixon Danielle A , Xekouki Paraskevi , Salaris Paola , Mustafa Omar , Prague Julia , Abbas Nadeem , Whitelaw Benjamin , Bodi Istvan , Aylwin Simon J B

Background: Lack of expression of MGMT (O-6-methylguanine-DNA methyltransferase) is associated with a better tumour response to temozolomide. There are no systematic studies of MGMT expression in pituitary tumour series.Aim: We introduced MGMT immunohistochemistry for all pituitary adenoma specimens in 2011. In this study we investigated the immunohistochemical expression of MGMT in a large series of pituitary adenomas, in order to determine (1) the over...

0 shares

ea0034p181 | Neoplasia, cancer and late effects | SFEBES2014

Inherited mutations in the SDH complex increase metastatic malignant potential of paragnglioma and phaeochromocytoma tumours

Jafar-Mohammadi Bahram , Izatt Louise , Schulte Klaus-Martin , Carroll Paul V , McGowan Barbara M , Powrie Jake K , Whitelaw Benjamin C , Sarker Debashis , Diaz-Cano Salvador , Aylwin Simon J B

Phaeochromocytomas (PCC) and paraganglioma (PGL) are neural crest tumours arising from the chromaffin producing cells of the adrenal medulla or sympathetic/parasympathetic system respectively. Recently, in part due to advances in high throughput sequencing, our understanding of the genetic predisposition to these tumours has greatly increased. To date, 13 genes have been implicated in the pathogenesis of these conditions (ten available for testing at our centre). Recent studie...

0 shares

ea0056p41 | Adrenal cortex (to include Cushing's) | ECE2018

Outcomes of patients undergoing surgery for primary aldosteronism based on adrenal venous sampling and/or radiological lateralisation indicate a role for both modalities in case selection

Davis Lauramay , Lewis Dylan , Clough Jennifer , Whitelaw Benjamin C , Gilbert Jackie , Diaz-Cano Salvador , Taylor David R , Vincent Royce P , Hubbard Jonathan , Galata Gabriele , Schulte Klaus-Martin , Aylwin Simon J B

Background: Adrenal venous sampling (AVS) is considered the gold standard for lateralisation of aldosterone production in patients with primary aldosteronism (PA). However, in some patients AVS is not technically successful and management may depend on radiological findings.Aim: To determine 1) the success rate of AVS and 2) the outcomes after surgery related to the lateralisation modality.Method: 156 patients were included who pre...

0 shares

ea0056p140 | Endocrine tumours and neoplasia | ECE2018

Achievement of therapeutic mitotane concentrations in management of advanced adrenocortical cancer: a single centre experience in 47 patients

Bakhit Mohamed , Whitelaw Benjamin C , Gilbert Jackie , Coskeran Patsy , Diaz-Cano Salvador , Taylor David R , Taylor Norman T , Ghatore Lea , Lewis Dylan , Vivian Gillian , Sarker Debashis , Ross Paul , Davis Laura May , Clough Jennifer , Hubbard Johnathan G , Galata Gabriele , Prachalias Andreas , Schulte Klaus-Martin , Aylwin Simon J B

Introduction: Multi-modal therapy for adrenocortical carcinoma (ACC) includes surgery, therapy with the adrenolytic agent mitotane and systemic chemotherapy. Achievement of therapeutic mitotane concentrations (≥14 mg/l) has been related to improved outcomes.Aim: To evaluate the effectiveness of a defined* high dose protocol mitotane therapy in patients with advanced ACC (stages III and IV).Methods: Review of patients presenti...

0 shares

Endocrine Abstracts

Hyperprolactinaemia resistant to dopamine agonist due to an ectopic source of prolactin arising from a Uterine Tumour Resembling Ovarian Sex Cord Tumours (UTROCST)

Expression of MGMT in a large series of pituitary adenomas: lactotroph and corticotroph adenomas are more likely to be MGMT-negative than somatotroph and gonadotroph adenomas

Inherited mutations in the SDH complex increase metastatic malignant potential of paragnglioma and phaeochromocytoma tumours

Outcomes of patients undergoing surgery for primary aldosteronism based on adrenal venous sampling and/or radiological lateralisation indicate a role for both modalities in case selection

Achievement of therapeutic mitotane concentrations in management of advanced adrenocortical cancer: a single centre experience in 47 patients

BiosciAbstracts